Autolus Therapeutics plc Deferred Costs
Autolus Therapeutics plc (AUTL) had Deferred Costs of $2.64 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets
us-gaap:DeferredCostsCurrentAndNoncurrent · last filed 2026-08-11
- 2026-06-30: Deferred Costs $2.64M.
- 2026-03-31: Deferred Costs $2.62M.
- 2025-12-31: Deferred Costs $3.43M.
- 2025-09-30: Deferred Costs $3.38M.
| Period end | Deferred Costs |
|---|---|
| 2026-06-30 | $2.64M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.62M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $3.43M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $3.38M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.86M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $2.42M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $2.32M 10-K · filed 2026-03-27 |
| 2023-12-31 | $1.79M 10-K · filed 2025-03-20 |
| 2022-12-31 | $1.49M 10-K · filed 2024-03-21 |
| 2021-12-31 | $1.07M 20-F · filed 2023-03-07 |
| 2020-12-31 | $3.01M 20-F · filed 2022-03-10 |
| 2019-12-31 | $0.00 20-F · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |